Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Cytokinetics, Inc. at the RBC Capital Markets Global Healthcare Conference
    Feb 22, 2018 10:00 AM EST

    Cytokinetics, Inc. at the RBC Capital Markets Global Healthcare Conference
    Feb 22, 2018 10:00 AM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
  Company Provides 2018 Financial Guidance and Expected Milestones;  Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phase 2 Clinical Trial
Toggle Summary Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital Markets Global Healthcare Conference on Thursday, February 22,
Toggle Summary Cytokinetics Names Robert Califf, M.D., to Board of Directors
Appointment Strengthens Regulatory, Global Clinical Research and Cardiology Expertise as Company Advances Its Development Pipeline and Executes Against Its Vision 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 15, 2018
SOUTH SAN FRANCISCO, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 15, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a

EVENTS

There are currently no events to display.